Sugi Predict

Sugi Predict / Compounds / SCHEMBL2369249

SCHEMBL2369249

SCHEMBL2369249

CC(C)(C)OC(=O)N[C@H](CCCNC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.64
▸ FOLH1 Q04609 3/20 0.63
▸ KLK7 P49862 2/20 0.61
▸ KLK5 Q9Y337 2/20 0.61
▸ PPARA Q07869 1/20 0.57
▸ SIRT2 Q8IXJ6 1/20 0.57
▸ SIRT1 Q96EB6 1/20 0.57
▸ ITGB3 P05106 2/20 0.56
▸ ITGA2B P08514 1/20 0.56
▸ CPB1 P15086 1/20 0.56
▸ CPB2 Q96IY4 1/20 0.56
▸ CTSK P43235 2/20 0.55
▸ SYK P43405 1/20 0.55
▸ MMP2 P08253 1/20 0.54
▸ MMP9 P14780 1/20 0.54
▸ TGM2 P21980 1/20 0.54
▸ ITGAV P06756 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1374918 1.00 MAPT (0.64) MAPTFOLH1KLK7KLK5PPARA
SCHEMBL1374913 1.00 MAPT (0.64) MAPTFOLH1KLK7KLK5PPARA
SCHEMBL3210903 0.97 MAPT (0.68) MAPTFOLH1KLK7KLK5PPARA
SCHEMBL2334326 0.97 MAPT (0.68) MAPTFOLH1KLK7KLK5PPARA
SCHEMBL2334319 0.97 MAPT (0.68) MAPTFOLH1KLK7KLK5PPARA
SCHEMBL918813 0.95 SYK (0.60) MAPTFOLH1KLK7KLK5PPARA
SCHEMBL1021938 0.95 SYK (0.60) MAPTFOLH1KLK7KLK5PPARA
SCHEMBL4958981 0.95 SYK (0.60) MAPTFOLH1KLK7KLK5PPARA
SCHEMBL8955505 0.93 KLK7 (0.64) MAPTFOLH1KLK7KLK5ITGB3
SCHEMBL6621271 0.93 MAPT (0.60) MAPTFOLH1KLK7KLK5PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622966-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF Radionetics Oncology, Inc. (US) 2025-10-01 — — EP disclosed
US-12364702-B2 Highly active sting protein agonist compound ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2025-07-22 — — US disclosed
US-20250213735-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2025-07-03 — — US disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
US-20240287093-A1 HIGH ACTIVITY STING PROTEIN AGONIST ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2024-08-29 — — US disclosed
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 — — US disclosed
US-20240189320-A1 HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2024-06-13 — — US disclosed
WO-2024112612-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-05-30 — — WO disclosed
EP-3842437-B1 HIGH ACTIVITY STING PROTEIN AGONIST ADLAI NORTYE BIOPHARMA CO LTD (CN) 2024-04-10 — — EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 — — US disclosed
WO-2015084998-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. (US) 2015-06-11 — — WO disclosed
US-20140134132-A1 CYCLIC PEPTIDES AND USE AS MEDICINES NOVARTIS AG (CH) 2014-05-15 — — US disclosed
US-20140134132-A1 CYCLIC PEPTIDES AND USE AS MEDICINES NOVARTIS AG (CH) 2014-05-15 — — US disclosed
EP-2539358-A1 PEPTIDE ANALOGUES Pfizer Limited (GB) 2013-01-02 — — EP disclosed
WO-2011104649-A1 PEPTIDE ANALOGUES PFIZER LIMITED (GB) 2011-09-01 — — WO disclosed
WO-2009146802-A1 MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI-AVENTIS (FR) 2009-12-10 — — WO disclosed
CN-1168702-C Movel acyl pseudodipeoptides, prepn method and pharmaceutical compsns. contg. same OMҩҵ 2004-09-29 — — CN disclosed
CN-1434795-A Acylated Pseudodipeptides with Functionalized Auxiliary Branches OM PHARMA (CH) 2003-08-06 — — CN disclosed
CN-1306504-A Movel acyl pseudodipeoptides, prepn method and pharmaceutical compsns. contg. same OM PHARMA (CH) 2001-08-01 — — CN disclosed
EP-0446699-A1 Inhibitors of nitric oxide biosynthesis MERRELL PHARMACEUTICALS INC. (US) 1991-09-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287093-A1 HIGH ACTIVITY STING PROTEIN AGONIST STING1, IRF3, MAVS MAPT 4229/4885FOLH1 3128/4885KLK7 2447/4885
US-12364702-B2 Highly active sting protein agonist compound STING1, IRF3, MAVS MAPT 3558/4885FOLH1 3469/4885KLK7 1847/4885
US-20250213735-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R MAPT 2444/4885FOLH1 335/4885KLK7 462/4885
US-20140134132-A1 CYCLIC PEPTIDES AND USE AS MEDICINES PPIF, VIP, FKBP1B MAPT 2692/4885FOLH1 839/4885KLK7 3469/4885
US-20240189320-A1 HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND STING1, IRF3, MAVS MAPT 3558/4885FOLH1 3469/4885KLK7 1847/4885
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R MAPT 2444/4885FOLH1 335/4885KLK7 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.